What’s Ahead For CAR-T Play Kite Pharma?

After having a magnificent embark to 2017, Kite Pharma shares have dropped recently on concerns over a patient death due to cerebral edema, putting at risk its lead candidate.

Based on the profile of the only KTE-C19 patient in

300 to die of edema, it seems unlikely that more edema deaths will occur. Read More